Latest:
Dr. Maki on the Utility of IDH1/2 Inhibitors in Chondrosarcoma
Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of IDH1/2 inhibitors in chondrosarcoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Robert G. Uzzo, MD
Latest:
Dr. Uzzo on Biomarker Development for RCC
Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).
Robert H. I. Andtbacka, MD
Latest:
Dr. Andtbacka on Optimal Use of T-VEC in Melanoma
Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the optimal use of talimogene laherparepvec (T-VEC) in patients with melanoma.
Robert I. Haddad, MD
Latest:
Staging System for HPV-Related Oropharynx Cancer Paves Way for Change
A new staging system for head and neck cancers recognizes that patients with oropharyngeal malignancies associated with the human papillomavirus often have an excellent prognosis, but efforts to deintensify therapy for this population based on a fresh understanding of favorable risk factors may be premature.
Robert J. Arceci, MD, PhD
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis
Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Robert J. Cerfolio, MD
Latest:
Dr. Cerfolio on the Importance of Specialized Care in Lung Cancer
Robert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the importance of specialized care in lung cancer and sheds light on the current outlook of the disease.
Robert J. Kreitman, MD
Latest:
Dr. Kreitman on Ongoing Research With Moxetumomab Pasudotox in Hairy Cell Leukemia
Robert J. Kreitman, MD, senior investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, discusses ongoing research with moxetumomab pasudotox-tdfk (Lumoxiti) in patients with hairy cell leukemia (HCL).